IDH1 and neoplasm: Also similar was the observation that patients harbouring non-R132H IDH1/2-mutated tumours survived significantly longer; the hazard ratio (HR) of patients harbouring non-R132H IDH1/2- mutated tumours (n = 37) versus IDH1R132H-mutated tumours (n = 177) was 0.20 (95% CI [0.047, 0.837], p = 0.028 Fig. 3c).